Canaccord Genuity Remains a Hold on Illumina (ILMN)

Business Insider

a day ago

In a report released today, Kyle Mikson CFA from Canaccord Genuity maintained a Hold rating on Illumina (ILMN – Research Report), with a price target of $99.00. The company's shares closed today at $87.98.
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
According to TipRanks, Mikson CFA is an analyst with an average return of -11.7% and a 31.25% success rate. Mikson CFA covers the Healthcare sector, focusing on stocks such as Illumina, Akoya Biosciences, and Exagen.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Illumina with a $107.33 average price target.
Based on Illumina's latest earnings release for the quarter ending March 30, the company reported a quarterly revenue of $1.04 billion and a net profit of $131 million. In comparison, last year the company earned a revenue of $1.08 billion and had a GAAP net loss of $126 million
Based on the recent corporate insider activity of 56 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ILMN in relation to earlier this year. Last month, Ankur Dhingra, the SVP & CFO of ILMN bought 6,100.00 shares for a total of $495,381.00.